Back to Browse Journals » Patient Preference and Adherence » Volume 2

Patient’s compliance with allergen immunotherapy

Authors Cristoforo Incorvaia, Marina Mauro, Erminia Ridolo, Paola Puccinelli, Massimiliano Liuzzo, et al

Published Date September 2008 Volume 2008:2 Pages 247—251

DOI http://dx.doi.org/10.2147/PPA.S3806

Published 15 September 2008

Cristoforo Incorvaia1, Marina Mauro2, Erminia Ridolo3, Paola Puccinelli4, Massimiliano Liuzzo4, Silvia Scurati4, Franco Frati4,5

1Allergy/Pulmonary rehabilitation Unit, ICP Hospital, Milan, Italy; 2Allergy Unit, Sant’Anna Hospital, Como, Italy; 3University Department of Clinical Sciences, Parma, Italy; 4Medical and Scientific Department, Stallergenes, Milan, Italy; 5Pediatrics, University Department of Medical and Surgical Specialty and Public Health, Perugia, Italy

Background: Allergen immunotherapy (IT) is an effective treatment of respiratory allergy, but requires strict rules of performance. This makes compliance particularly relevant, but thus far only a few studies have investigated this issue.

Methods: We reviewed all the available articles on compliance and adherence with IT in its different forms of administration, ie, subcutaneous (SCIT), sublingual (SLIT), and local nasal (LNIT).

Results: Early studies, when only SCIT was available, reported a low compliance, ranging from 45% to 60%, but the demanding schedules used, with very frequent injections, accounted for this outcome, as shown by patients’ recognition of inconvenience as the major cause of noncompliance. The most recent studies reported a good compliance, estimated in 75% to 90%, to both SCIT and SLIT, inconvenience remaining the major cause of noncompliance, followed by cost of the treatment. The only study addressing LNIT found a very poor compliance (27%), the major cause being the side effects, with repeated nasal reactions to the allergen extract.

Conclusions: Adequate education of patients and optimization of administration schedules, with fine balancing between dose effectiveness and cost, are the factors most likely to achieve further improvement of compliance with IT.

Keywords: allergen immunotherapy, subcutaneous, sublingual, local nasal, compliance, adherence

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other articles by this author:

Effect of noninvasive mechanical ventilation in elderly patients with hypercapnic acute-on-chronic respiratory failure and a do-not-intubate order

Paolo Scarpazza, Cristoforo Incorvaia, Giuseppe di Franco, Stefania Raschi, Pierfranco Usai, et al

International Journal of Chronic Obstructive Pulmonary Disease 2008, 3:797-801

Published Date: 30 October 2008

Current and future applications of the anti-IgE antibody omalizumab

Cristoforo Incorvaia, Marina Mauro, Gian Galeazzo Riario-Sforza, Franco Frati, Francesco Tarantini, Maurizio Caserini

Biologics: Targets and Therapy 2008, 2:67-73

Published Date: 26 March 2008

Impairment of small airways in COPD patients with frequent exacerbations and effects of treatment with tiotropium

Cristoforo Incorvaia, Gian Galeazzo Riario-Sforza, Chiara Pravettoni, Mona-Rita Yacoub, Franco Frati

International Journal of Chronic Obstructive Pulmonary Disease 2008, 3:123-126

Published Date: 18 March 2008

Readers of this article also read:

Twice-daily versus once-daily antiretroviral therapy and coformulation strategies in HIV-infected adults: benefits, risks, or burden?

Nachega JB, Rosenkranz B, Pham PA

Patient Preference and Adherence 2011, 5:645-651

Published Date: 28 December 2011

DataGenno: building a new tool to bridge molecular and clinical genetics

Fabricio F Costa, Luciano S Foly, Marcelo P Coutinho

The Application of Clinical Genetics 2011, 4:45-54

Published Date: 18 March 2011

Epigenomics in cancer management

Fabricio F Costa

Cancer Management and Research 2010, 2:255-265

Published Date: 27 October 2010

Hepatitis C virus infection and risk of cancer: a population-based cohort study

Lars Haukali Omland, Dora Körmendiné Farkas, Peter Jepsen, et al

Clinical Epidemiology 2010, 2:179-186

Published Date: 24 June 2010

Prolonged rupture of membranes in term infants: should all babies be screened?

Christopher Flannigan, Martina Hogan

Clinical Audit 2010, 2:1-6

Published Date: 9 February 2010

Tenofovir-associated bone density loss

Iwen F Grigsby, Lan Pham, Louis M Mansky, et al

Therapeutics and Clinical Risk Management 2010, 6:41-47

Published Date: 24 December 2009

Applications of gold nanoparticles in cancer nanotechnology

Weibo Cai, Ting Gao, Hao Hong, Jiangtao Sun

Nanotechnology, Science and Applications 2008, 1:17-32

Published Date: 19 September 2008